Clinical trial

A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children

NCT00569192

Study summary

ClinicalTrials.gov

A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention 0.135mg MAP0010 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention 0.25mg MAP0010 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-12-01

PhasePHASE3

Conditions

Asthmaverified · MONDO: asthma

Interventions

0.135mg MAP0010DRUG

0.25mg MAP0010DRUG

PlaceboDRUG

Sponsors & collaborators

Allerganlead sponsor

MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergancollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00569192 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.